Blog
RSS FeedPosted by Michael Wonder on 06 May 2021
ICER to assess treatment for severe asthma
6 May 2021 - Report will be subject of Midwest CEPAC meeting in November 2021; draft scoping document open to ...
Posted by Michael Wonder on 05 Sep 2016
EMA publishes EPAR for Aerivio Spiromax
5 September 2016 - The EMA has published an EPAR for Teva Pharmaceuticals' version of GSK's Seretide/Advair. ...
Posted by Michael Wonder on 19 Aug 2016
European Commission grants marketing authorisation for Teva’s Cinqaero (reslizumab)
18 August 2016 - First intravenous anti-IL-5 biologic therapy for severe eosinophilic asthma now approved in Europe. ...
Posted by Michael Wonder on 08 Jul 2016
Novartis announces FDA approval of Xolair (omalizumab) for paediatric allergic asthma
7 July 2016 - Extension of indication makes Xolair the first and only approved biologic for pediatric patients six years and ...
Posted by Michael Wonder on 26 Jun 2016
Teva receives CHMP positive opinion for Cinqaero (reslizumab)
24 June 2016 - Add-on therapy targeting IL-5 in adults with severe eosinophilic asthma pending marketing authorization in Europe. ...
Posted by Michael Wonder on 09 Jun 2016
NICE publishes second appraisal consultation for Nucala (mepolizumab)
9 June 2016 - NICE has published a second appraisal consultation for GSK's Nucala (mepolizumab). ...
Posted by Michael Wonder on 31 May 2016
Schedule of Pharmaceutical Benefits - 1 June 2016 update
1 June 2016 - The June 2016 issue of the Schedule is out and now in effect. ...
Posted by Michael Wonder on 17 May 2016
Prescription medicines: new or extended uses approved by the TGA
17 May 2016 - The TGA has published a list of the medicines it approved for new uses (new indications) ...
Posted by Michael Wonder on 04 May 2016
Call for patient input on a submission from Teva Pharmaceuticals for reslizumab
4 May 2016 - CADTH has received notice of a pending submission from Teva Pharmaceuticals for reslizumab for use by patients ...
Posted by Michael Wonder on 02 May 2016
Mepolizumab in severe asthma: additional benefit is not proven
2 May 2016 - Appropriate comparator therapy not implemented so the indirect comparison is unsuitable. ...
Posted by Michael Wonder on 01 May 2016
Teva announces FDA approval of ProAir RespiClick (salbutamol sulphate) inhalation powder for paediatric asthma patients ages 4 to 11
29 April 2016 - Teva Pharmaceuticals announced today that the U.S. FDA has approved ProAir RespiClick (salbutamol sulphate) inhalation powder for ...
Posted by Michael Wonder on 08 Apr 2016
NICE appraisal consultation for mepolizumab (Nucala) for patients with severe eosinophilic asthma
4 April 2016 - The Department of Health has asked NICE to produce guidance on using mepolizumab in the NHS in ...
Posted by Michael Wonder on 23 Mar 2016
FDA approves Cinqair to treat severe asthma
23 March 2016 - The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for ...
Posted by Michael Wonder on 01 Mar 2016
New Zealand Pharmaceutical Schedule - 1 March 2016 update
1 March 2016 - the March 2016 issue of the Schedule sees the listing of a number of new medicines/combination ...
Posted by Michael Wonder on 14 Dec 2015
Budesonide with eformoterol (Symbicort Turbuhaler and Vannair) proposal with Astra Zeneca
15 December 2015 - PHARMAC is seeking feedback on a proposal involving budesonide with eformoterol inhalers (Symbicort Turbuhaler and Vannair), which ...